BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim KJ, Kim JH, Lee SJ, Lee EJ, Shin EC, Seong J. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. Oncotarget. 2017;8:41242-41255. [PMID: 28465485 DOI: 10.18632/oncotarget.17168] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
Number Citing Articles
1 Park JH, Kim HY, Lee A, Seo YK, Kim IH, Park ET, Kang MS, Park SJ, Park S. Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1. Int J Radiat Oncol Biol Phys 2021;110:510-20. [PMID: 33383126 DOI: 10.1016/j.ijrobp.2020.12.031] [Reference Citation Analysis]
2 Tran L, Theodorescu D. Determinants of Resistance to Checkpoint Inhibitors. Int J Mol Sci 2020;21:E1594. [PMID: 32111080 DOI: 10.3390/ijms21051594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
3 Zhang L, Yan L, Niu H, Ma J, Yuan BY, Chen YH, Zhuang Y, Hu Y, Zeng ZC, Xiang ZL. A nomogram to predict prognosis of patients with unresected hepatocellular carcinoma undergoing radiotherapy: a population-based study. J Cancer 2019;10:4564-73. [PMID: 31528220 DOI: 10.7150/jca.30365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kim KJ, Lee HW, Seong J. Combination therapy with anti-T-cell immunoglobulin and mucin-domain containing molecule 3 and radiation improves antitumor efficacy in murine hepatocellular carcinoma. J Gastroenterol Hepatol. 2020;. [PMID: 33217056 DOI: 10.1111/jgh.15319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
6 Zeng P, Shen D, Zeng CH, Chang XF, Teng GJ. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Curr Oncol Rep 2020;22:76. [PMID: 32596779 DOI: 10.1007/s11912-020-00943-6] [Reference Citation Analysis]
7 Yu JI, Lee SJ, Lee J, Lim HY, Paik SW, Yoo GS, Choi C, Park HC. Clinical significance of radiotherapy before and/or during nivolumab treatment in hepatocellular carcinoma. Cancer Med 2019;8:6986-94. [PMID: 31588679 DOI: 10.1002/cam4.2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
8 Shi LZ, Bonner JA. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis. Int J Mol Sci 2021;22:12295. [PMID: 34830176 DOI: 10.3390/ijms222212295] [Reference Citation Analysis]
9 Lurje I, Werner W, Mohr R, Roderburg C, Tacke F, Hammerich L. In Situ Vaccination as a Strategy to Modulate the Immune Microenvironment of Hepatocellular Carcinoma. Front Immunol 2021;12:650486. [PMID: 34025657 DOI: 10.3389/fimmu.2021.650486] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Park J, Park JW, Kang MK. Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma. Yeungnam Univ J Med 2019;36:192-200. [PMID: 31620633 DOI: 10.12701/yujm.2019.00269] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Wimmer S, Deloch L, Hader M, Derer A, Grottker F, Weissmann T, Hecht M, Gostian AO, Fietkau R, Frey B, Gaipl US. Hypofractionated Radiotherapy Upregulates Several Immune Checkpoint Molecules in Head and Neck Squamous Cell Carcinoma Cells Independently of the HPV Status While ICOS-L Is Upregulated Only on HPV-Positive Cells. Int J Mol Sci 2021;22:9114. [PMID: 34502022 DOI: 10.3390/ijms22179114] [Reference Citation Analysis]
12 Shanker MD, Liu HY, Lee YY, Stuart KA, Powell EE, Wigg A, Pryor DI. Stereotactic radiotherapy for hepatocellular carcinoma: Expanding the multidisciplinary armamentarium. J Gastroenterol Hepatol 2021;36:873-84. [PMID: 32632941 DOI: 10.1111/jgh.15175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Meyer J, Singal AG. Stereotactic ablative radiotherapy for hepatocellular carcinoma: History, current status, and opportunities. Liver Transpl 2018;24:420-7. [DOI: 10.1002/lt.24991] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
14 Choi SH, Seong J. Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma? Yonsei Med J. 2018;59:912-922. [PMID: 30187697 DOI: 10.3349/ymj.2018.59.8.912] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
15 Lewis S, Dawson L, Barry A, Stanescu T, Mohamad I, Hosni A. Stereotactic body radiation therapy for hepatocellular carcinoma: from infancy to ongoing maturity. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100498] [Reference Citation Analysis]
16 Bresnahan E, Lindblad KE, Ruiz de Galarreta M, Lujambio A. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma. Clin Cancer Res 2020;26:5276-86. [PMID: 32327473 DOI: 10.1158/1078-0432.CCR-19-2923] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
18 Liao XY, Liu CY, He JF, Wang LS, Zhang T. Combination of checkpoint inhibitors with radiotherapy in esophageal squamous cell carcinoma treatment: A novel strategy. Oncol Lett 2019;18:5011-21. [PMID: 31612012 DOI: 10.3892/ol.2019.10893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
19 Liu C, Wang P, Sun Y, Dou X, Hu X, Zou W, Sun Y, Hu Q, Yue J. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer. Front Oncol 2022;12:756811. [DOI: 10.3389/fonc.2022.756811] [Reference Citation Analysis]
20 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Cho S, Lee B, Park W, Huang X, Kim DH. Photoperiodic Flower Mimicking Metallic Nanoparticles for Image-Guided Medicine Applications. ACS Appl Mater Interfaces 2018;10:27570-7. [PMID: 30086228 DOI: 10.1021/acsami.8b09596] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
22 Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2416-2429 [PMID: 31171886 DOI: 10.3748/wjg.v25.i20.2416] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 31] [Article Influence: 11.7] [Reference Citation Analysis]
23 Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer 2020;8:e000340. [PMID: 32461345 DOI: 10.1136/jitc-2019-000340] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
24 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
25 Liu X, Qin S. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges. Oncologist 2019;24:S3-S10. [PMID: 30819826 DOI: 10.1634/theoncologist.2019-IO-S1-s01] [Cited by in Crossref: 24] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
26 Pierini S, Mishra A, Perales-Linares R, Uribe-Herranz M, Beghi S, Giglio A, Pustylnikov S, Costabile F, Rafail S, Amici A, Facciponte JG, Koumenis C, Facciabene A. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression. J Immunother Cancer 2021;9:e001636. [PMID: 33563772 DOI: 10.1136/jitc-2020-001636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Guardascione M, Toffoli G. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E6302. [PMID: 32878115 DOI: 10.3390/ijms21176302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Zhang HE, Henderson JM, Gorrell MD. Animal models for hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis 2019;1865:993-1002. [PMID: 31007176 DOI: 10.1016/j.bbadis.2018.08.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
29 Sampath S, Won H, Massarelli E, Li M, Frankel P, Vora N, Vora L, Maghami E, Kortylewski M. Combined modality radiation therapy promotes tolerogenic myeloid cell populations and STAT3-related gene expression in head and neck cancer patients. Oncotarget 2018;9:11279-90. [PMID: 29541413 DOI: 10.18632/oncotarget.24397] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
30 Smith WH, Law AS, Hulkower M, McGee HM, Lehrer EJ, Schwartz M, Taouli B, Sung M, Buckstein M. The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma. Acta Oncol 2020;59:940-3. [PMID: 32441551 DOI: 10.1080/0284186X.2020.1769860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Miao L, Zhang Z, Ren Z, Li Y. Application of Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:699060. [PMID: 34513678 DOI: 10.3389/fonc.2021.699060] [Reference Citation Analysis]
32 Zhong L, Wu D, Peng W, Sheng H, Xiao Y, Zhang X, Wang Y. Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma. Front Oncol 2021;11:686621. [PMID: 34094988 DOI: 10.3389/fonc.2021.686621] [Reference Citation Analysis]
33 Seo I, Lee HW, Byun SJ, Park JY, Min H, Lee SH, Lee JS, Kim S, Bae SU. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer. J Immunother Cancer 2021;9:e001610. [PMID: 33692216 DOI: 10.1136/jitc-2020-001610] [Reference Citation Analysis]
34 Byun HK, Kim KJ, Han SC, Seong J. Effect of Interleukin-7 on Radiation-Induced Lymphopenia and Its Antitumor Effects in a Mouse Model. Int J Radiat Oncol Biol Phys 2021;109:1559-69. [PMID: 33321193 DOI: 10.1016/j.ijrobp.2020.12.004] [Reference Citation Analysis]
35 Lee BM, Seong J. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World J Gastroenterol 2021; 27(10): 919-927 [PMID: 33776363 DOI: 10.3748/wjg.v27.i10.919] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Yoo GS, Ahn WG, Kim SY, Kang W, Choi C, Park HC. Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol 2021;27:144-56. [PMID: 33280350 DOI: 10.3350/cmh.2020.0095] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Keam S, Gill S, Ebert MA, Nowak AK, Cook AM. Enhancing the efficacy of immunotherapy using radiotherapy. Clin Transl Immunology 2020;9:e1169. [PMID: 32994997 DOI: 10.1002/cti2.1169] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
38 Nishida N, Kudo M. Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatol Res 2018;48:622-34. [PMID: 29734514 DOI: 10.1111/hepr.13191] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 8.3] [Reference Citation Analysis]
39 Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res 2019;25:7576-84. [PMID: 31540976 DOI: 10.1158/1078-0432.CCR-19-0795] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
40 Gong J, Le TQ, Massarelli E, Hendifar AE, Tuli R. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. J Immunother Cancer 2018;6:46. [PMID: 29866197 DOI: 10.1186/s40425-018-0361-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 74] [Article Influence: 18.0] [Reference Citation Analysis]
41 Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:1025-35. [PMID: 34695377 DOI: 10.1016/S2468-1253(21)00305-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Anand S, Chan TA, Hasan T, Maytin EV. Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review). Pharmaceuticals (Basel) 2021;14:447. [PMID: 34068491 DOI: 10.3390/ph14050447] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Lee HA, Rim CH. Efficacy of Local Treatments for Hepatocellular Carcinoma Involving the Inferior Vena Cava and/or Right Atrium. J Hepatocell Carcinoma 2020;7:435-46. [PMID: 33376712 DOI: 10.2147/JHC.S285357] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Keane FK, Hong TS, Zhu AX. Evolving Systemic Therapy in Hepatocellular Carcinoma: Current Management and Opportunities for Integration With Radiotherapy. Semin Radiat Oncol 2018;28:332-41. [PMID: 30309643 DOI: 10.1016/j.semradonc.2018.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
45 Lippitz BE, Harris RA. A translational concept of immuno-radiobiology. Radiother Oncol 2019;140:116-24. [PMID: 31271996 DOI: 10.1016/j.radonc.2019.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
46 Kim JW, Lee IJ. Exploring the mythical abscopal effect: Radiation and programmed cell death protein 1 (PD-1) blockade for hepatocellular carcinoma. Clin Mol Hepatol 2021;27:103-6. [PMID: 33317257 DOI: 10.3350/cmh.2020.0297] [Reference Citation Analysis]
47 Liu CM, Huang BS, Yen YH, Wang YM, Huang EY, Hsu HC, Huang TT, Yang YH, Cheng JY. Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis. J Hepatocell Carcinoma 2021;8:963-73. [PMID: 34434903 DOI: 10.2147/JHC.S323302] [Reference Citation Analysis]
48 Tong VJW, Shelat VG, Chao YK. Clinical application of advances and innovation in radiation treatment of hepatocellular carcinoma. J Clin Transl Res 2021;7:811-33. [PMID: 34988334] [Reference Citation Analysis]